Aarti Drugs Ltd. stands as a prominent Indian pharmaceutical company, specializing in the manufacturing of Active Pharmaceutical Ingredients (APIs), Pharma Intermediates, and Specialty Chemicals. Established in 1984, the company is a key part of the $900 Million Aarti Group of Industries and boasts a robust Research and Development Division located in Tarapur, Maharashtra Industrial Development Corporation (MIDC).
Incorporated in September 1984, Aarti Drugs Limited (ADL) has grown to become a significant player in the global pharmaceutical landscape. The company's operations encompass the manufacturing of APIs, Pharma Intermediates, and Specialty Chemicals, and it also produces Formulations through its wholly-owned subsidiary, Pinnacle Life Science Private Limited.
Aarti Drugs Ltd. is a leading global producer of over 50 API molecules across critical therapeutic categories including antibiotics, antiprotozoal, anti-inflammatory, anti-diabetic, and anti-fungal drugs. The company holds the distinction of being the largest manufacturer of Fluoroquinolones, Tinidazole, Metronidazole Benzoate, Celecoxib, Nimesulide, and Ketoconazole worldwide. Furthermore, it is among the top global producers of Metformin.
The company's extensive product range under APIs includes key molecules such as Ciprofloxacin Hydrochloride, Metronidazole, Metformin HCL, Ketoconazole, and Ofloxacin. Beyond these, their portfolio also encompasses vitamins, sedatives, and drugs for anti-inflammatory, anti-asthma, anti-arthritis, anti-fungal, anti-diabetic, anti-osteoporosis, anti-cholinergic, and anti-depressant applications.
Aarti Drugs Ltd. exports its APIs and Specialty Chemicals to over 100 countries globally, catering to both domestic and international markets, with a significant portion of its revenue derived from its Indian operations.
Established in 1984 and operating as a crucial component of the $1000 million Aarti Group of Industries, Aarti Drugs Ltd. (ADL) is a leading manufacturer and seller of Active Pharmaceutical Ingredients (APIs), Pharma Intermediates, Specialty Chemicals, and Formulations. The company has cemented its reputation as a reliable global partner within the pharmaceutical sector, serving a diverse clientele across various therapeutic categories.
For the third quarter of FY25 (standalone business), approximately 64% of revenues originated from the domestic market, while 36% came from exports. Within the API business segment for Q3 FY25, the antibiotic therapeutic category contributed approximately 38.6% to sales, followed by anti-diabetic at around 16.1%, anti-protozoal at approximately 16.5%, anti-inflammatory at around 11.9%, and antifungal at about 12%. The remaining categories accounted for approximately 5% of total API sales.
Aarti Drugs Ltd. holds a market capitalization of ₹4,361 crore as of March 2025. The company has consistently demonstrated resilient financial performance, even amidst challenging market conditions.
- Q4 FY25 Performance:
- Revenue: ₹676.76 Crore (as of March 2025)
- Net Profit: ₹62.77 Crore (as of March 2025)
- Net profit saw a 32.70% increase to ₹62.86 crore in the quarter ended March 2025, compared to ₹47.37 crore in the corresponding quarter of the previous year (March 2024).
- Sales grew by 9.16% to ₹676.76 crore in the quarter ended March 2025, from ₹619.99 crore in the previous quarter (March 2024).
- Full Year FY24 Performance:
- For the fiscal year ended 2024, Aarti Drugs Ltd. reported a profit of ₹171.59 crore on a total income of ₹2,528.58 crore.
Aarti Drugs Ltd. has significantly expanded its production capacity, growing from 598,000 kg in 1993 to 25,716,000 kg by 2021. The company operates state-of-the-art manufacturing facilities that are complemented by robust research and development capabilities.
Its GMP-certified plant is equipped to manufacture key products such as Benzene Sulphonyl Chloride, Benzene Sulphonic Acid/ Sodium Salt, and Benzene Sulphonamide. Aarti Drugs also actively conducts research and development on critical product areas including antihistaminic/antiallergic, anti-inflammatory, and antidiabetic drugs.
Following recent inspections, the company's facility is considered to be in a minimally acceptable state of compliance with current good manufacturing practices (CGMP). This compliance enables Aarti Drugs to export key products, including Ciprofloxacin HCl API, Zolpidem Tartrate API, Raloxifene HCl API, Celecoxib API, and Niacin API, to the US market.
Furthermore, a greenfield project at the Tarapur Facility, focused on dermatology products, has commenced operations. A ramp-up of production for this facility is planned throughout the first half of FY '25.
As of March 2025, the promoter holding in Aarti Drugs Ltd. stands at 55.48%, a slight decrease from 55.67% as of June 2024. The company has a total workforce of 2,766 employees.
Aarti Drugs Ltd. upholds high standards of corporate governance and continues to invest in enhancing its capabilities to effectively serve the growing global pharmaceutical market. With its strong manufacturing base, diverse product portfolio, and unwavering commitment to quality, Aarti Drugs is strategically positioned to leverage emerging opportunities within the pharmaceutical industry.
